window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : June 28, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Advanced Therapies

  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development,Therapeutic Areas

    etherna intratumoral mRNA/LNP platform advances toward IND studies in non-melanoma skin cancer

    etherna, a biotech company specialising in mRNA and lipid nanoparticle [...]

    May 5, 2026
  • Advanced Therapies,Drug Discovery & Development

    MaxCyte launches 96-well electroporation platform for cell therapy discovery

    MaxCyte, Inc. has launched ExPERT DTx, a 96-well electroporation platform [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Almirall meets guidance with 12.4% net sales growth and dermatology portfolio progress in 2025

    Almirall delivered net sales growth of 12.4% in 2025, surpassing [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Pharmaceuticals and therapeutics

    Abivax shows anti-fibrotic activity for obefazimod in IBD at ECCO 2026

    Abivax has presented new preclinical and clinical data for obefazimod [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Manufacturing & Supply Chain,Therapeutic Areas

    Hansa Biopharma’s BLA for imlifidase accepted by FDA

    Hansa Biopharma’s Biologics License Application (BLA) for imlifidase has been [...]

    May 5, 2026
  • Advanced Therapies,Drug Discovery & Development,Manufacturing & Supply Chain

    Lonza expands bioconjugate capabilities at Oss site to support ADC development

    Lonza expands its Advanced Synthesis capabilities at Oss, integrating ADC [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Oncoinvent to present 24-month Phase 1 ovarian cancer data for Radspherin at ESGO 2026

    Oncoinvent will present final 24-month follow-up data from its Phase [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development

    Scribe Therapeutics secures milestone $1.5BN collaboration with Eli Lilly for in vivo CRISPR program

    Scribe Therapeutics has achieved a second success milestone in its [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Therapeutic Areas

    Kidswell Bio and Treehill Partners launch US newco to advance cell therapy for paediatric cerebral palsy

    Kidswell Bio and Treehill Partners have launched a US-based regenerative [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Manufacturing & Supply Chain,Therapeutic Areas

    CellProthera acquires full rights to transendocardial catheter from Celyad Oncology

    CellProthera has acquired full rights to the transendocardial catheter originally [...]

    May 5, 2026
Previous456Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • InduPro licenses Lonza ADC technology for oncology programmes
    Categories: Biotech & Pharma Business, Drug Discovery & Development, Pharmaceuticals and therapeutics
  • Bionyra launches with $165M Series A to advance immunology biologics pipeline
    Categories: Biotech & Pharma Business, Drug Discovery & Development, Pharmaceuticals and therapeutics
  • Atsena advances gene therapy ATSN-201 into Phase 3 trial for inherited blindness
    Categories: Advanced Therapies, Clinical & Regulatory, Genomics and sequencing, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top